Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMGFV3Z)

Drug Name
Nizatidine Drug Info
Synonyms
Acinon; Antizid; Axid; Calmaxid; Cronizat; Distaxid; Galitidin; Gastrax; Naxidine; Niatidine; Nizatidina; Nizatidinum; Nizax; Nizaxid; Panaxid; Tazac; Ulcosol; Ulxid; Zanizal; Zinga; Axid Ar; Nizatidina [Spanish]; Nizatidinum [Latin]; Splendil ER; LY 139037; Acinon (TN); Axid (TN); LY-139037; Tazac (TN); ZE-101; ZL-101; Nizatidine (JAN/USP/INN); Nizatidine [USAN:BAN:INN:JAN]; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin; (E)-1-N'-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
Therapeutic ClassAntiulcer Agents
Cross-matching ID
PubChem CID
3033637
ChEBI ID
CHEMBL7601
CAS Number
CAS 76963-41-2
TTD Drug ID
D0Q9DK
VARIDT Drug ID
DR00263
INTEDE Drug ID
DR2187
ACDINA Drug ID
D00477

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Histidine metabolism 1.92 1.37e-2 16/22 (72.73%) ALDH2;AOC1;ALDH3A1;...
Ribosome 1.83 3.42e-2 113/158 (71.52%) RPS4Y1;MRPS2;MRPL23;...
Steroid hormone biosynthesis -1.61 4.77e-2 43/61 (70.49%) CYP3A5;HSD11B2;UGT2A3;...
Fluid shear stress and atherosclerosis -1.61 4.88e-2 123/139 (88.49%) GSTM4;GSTM1;ACVR2B;...
Necroptosis -1.63 4.74e-2 113/159 (71.07%) CAPN1;CYLD;IFNGR1;...
HIF-1 signaling pathway -1.63 4.86e-2 105/109 (96.33%) LDHA;IGF1R;MKNK2;...
Endocytosis -1.64 4.46e-2 198/252 (78.57%) ASAP2;RAB5C;AGAP1;...
Metabolism of xenobiotics by cytochrome P450 -1.64 4.58e-2 49/77 (63.64%) ADH1B;GSTK1;CYP3A5;...
Arginine biosynthesis -1.64 4.71e-2 17/22 (77.27%) OTC;GLUD2;ASL;...
IL-17 signaling pathway -1.66 4.12e-2 84/94 (89.36%) IL13;TNF;IL5;...
Parkinson disease -1.67 4.07e-2 176/249 (70.68%) NDUFA1;PSMC2;PSMA1;...
Human cytomegalovirus infection -1.68 3.84e-2 201/225 (89.33%) PRKCA;CCL4;MAPK3;...
Protein processing in endoplasmic reticulum -1.69 3.58e-2 127/171 (74.27%) EDEM2;ATF4;DNAJC3;...
Regulation of lipolysis in adipocytes -1.70 3.44e-2 52/55 (94.55%) ADCY6;PNPLA2;ADORA1;...
Thermogenesis -1.70 3.41e-2 173/232 (74.57%) NDUFA3;NDUFS7;NDUFAF3;...
N-Glycan biosynthesis -1.72 3.24e-2 38/50 (76%) STT3A;MGAT2;MAN1A1;...
Nicotinate and nicotinamide metabolism -1.72 3.28e-2 25/35 (71.43%) SIRT6;NNT;SIRT2;...
Sphingolipid metabolism -1.73 3.07e-2 32/49 (65.31%) SPTLC1;CERS2;SGPP1;...
TNF signaling pathway -1.75 2.83e-2 103/112 (91.96%) MAPK3;CASP7;MAP3K8;...
FoxO signaling pathway -1.76 2.95e-2 118/131 (90.08%) IGF1R;TGFBR2;IL7R;...
Proximal tubule bicarbonate reclamation -1.77 2.67e-2 21/23 (91.3%) AQP1;GLUD2;GLUD1;...
Vibrio cholerae infection -1.78 2.21e-2 44/50 (88%) PRKACG;CFTR;ATP6V1B2;...
Collecting duct acid secretion -1.83 1.41e-2 22/27 (81.48%) ATP6V1F;ATP6V0A1;ATP4B;...
PPAR signaling pathway -1.83 1.56e-2 66/74 (89.19%) SCP2;EHHADH;AQP7;...
Bile secretion -1.84 1.44e-2 68/90 (75.56%) ADCY7;UGT2B15;ATP1B3;...
Terpenoid backbone biosynthesis -1.89 7.31e-3 18/22 (81.82%) FNTA;ACAT1;MVD;...
Lysosome -1.90 4.27e-3 115/128 (89.84%) CTNS;CLTCL1;ATP6V0C;...
Non-alcoholic fatty liver disease -1.94 0.00e+0 126/155 (81.29%) SREBF1;MLXIPL;PRKAB2;...
Oxidative phosphorylation -2.02 0.00e+0 93/133 (69.92%) ATP4B;SDHA;PPA1;...
Mineral absorption -2.04 0.00e+0 48/60 (80%) FTL;SLC11A2;ATP7B;...
Ferroptosis -2.29 0.00e+0 36/41 (87.8%) FTL;ALOX15;SLC11A2;...
Steroid biosynthesis -2.40 0.00e+0 19/20 (95%) LIPA;FDFT1;LSS;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 6.66uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H